Nuclear Imaging for Cardiac Amyloidosis

Overview

Journal Heart Fail Rev

Date 2014 Nov 27

PMID 25424887

Citations 5

Authors

Walter Noordzij

Andor W J M Glaudemans

Simone Longhi

Riemer H J A Slart

Massimiliano Lorenzini

Bouke P C Hazenberg

Claudio Rapezzi

Affiliations

Soon will be listed here.

Abstract

Histological analysis of endomyocardial tissue is still the gold standard for the diagnosis of cardiac amyloidosis, but has its limitations. Accordingly, there is a need for non-invasive modalities to diagnose cardiac amyloidosis. Echocardiography and ultrasound and magnetic resonance imaging can show characteristics which may not be very specific for cardiac amyloid. Nuclear medicine has gained a precise role in this context: several imaging modalities have become available for the diagnosis and prognostic stratification of cardiac amyloidosis during the last two decades. The different classes of radiopharmaceuticals have the potential to bind different constituents of the amyloidotic infiltrates, with some relevant differences among the various aetiologic types of amyloidosis and the different organs and tissues involved. This review focuses on the background of the commonly used modalities, their present clinical applications, and future clinical perspectives in imaging patients with (suspected) cardiac amyloidosis. The main focus is on conventional nuclear medicine (bone scintigraphy, cardiac sympathetic innervation) and positron emission tomography.

Citing Articles

Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.

Rigopoulos A, Ali M, Abate E, Torky A, Matiakis M, Mammadov M Heart Fail Rev. 2019; 24(4):521-533.

PMID: 30790171 DOI: 10.1007/s10741-019-09776-3.

Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?.

Jonker D, Hazenberg B, Nienhuis H, Slart R, Glaudemans A, Noordzij W J Nucl Cardiol. 2018; 27(5):1774-1784.

PMID: 30374850 PMC: 7599160. DOI: 10.1007/s12350-018-01477-y.

Introduction to the Special Issue: Myocardial Imaging in Heart Failure.

Al-Mallah M Heart Fail Rev. 2017; 22(4):381-383.

PMID: 28620744 DOI: 10.1007/s10741-017-9633-4.

The Prevalence and Management of Systemic Amyloidosis in Western Countries.

Nienhuis H, Bijzet J, Hazenberg B Kidney Dis (Basel). 2016; 2(1):10-9.

PMID: 27536687 PMC: 4946260. DOI: 10.1159/000444206.

Radionuclide Imaging Applications in Cardiomyopathies and Heart Failure.

Harinstein M, Soman P Curr Cardiol Rep. 2016; 18(3):23.

PMID: 26841785 DOI: 10.1007/s11886-016-0699-8.

References

Lee V, Caldarone A, Falk R, Rubinow A, Cohen A . Amyloidosis of heart and liver: comparison of Tc-99m pyrophosphate and Tc-99m methylene diphosphonate for detection. Radiology. 1983; 148(1):239-42. DOI: 10.1148/radiology.148.1.6304810. View

Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y . Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001; 86(6):656-60. PMC: 1730035. DOI: 10.1136/heart.86.6.656. View

Kula R, Engel W, Line B . Scanning for soft-tissue amyloid. Lancet. 1977; 1(8002):92-3. DOI: 10.1016/s0140-6736(77)91102-3. View

Wieland D, Brown L, Rogers W, Worthington K, Wu J, Clinthorne N . Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981; 22(1):22-31. View

Perugini E, Guidalotti P, Salvi F, Cooke R, Pettinato C, Riva L . Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005; 46(6):1076-84. DOI: 10.1016/j.jacc.2005.05.073. View

Jacobson A, Lombard J, Banerjee G, Camici P . 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol. 2009; 16(1):113-21. DOI: 10.1007/s12350-008-9008-2. View

Sasano T, Abraham M, Chang K, Ashikaga H, Mills K, Holt D . Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol. 2008; 51(23):2266-75. DOI: 10.1016/j.jacc.2008.02.062. View

Aprile C, MARINONE G, Saponaro R, Bonino C, Merlini G . Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med. 1995; 22(12):1393-401. DOI: 10.1007/BF01791147. View

Hutt D, Quigley A, Page J, Hall M, Burniston M, Gopaul D . Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014; 15(11):1289-98. DOI: 10.1093/ehjci/jeu107. View

10.

Janssen S, Piers D, van Rijswijk M, Meijer S, MANDEMA E . Soft-tissue uptake of 99mTc-diphosphonate and 99mTc-pyrophosphate in amyloidosis. Eur J Nucl Med. 1990; 16(8-10):663-70. DOI: 10.1007/BF00998166. View

11.

Mitra D, Basu S . Equilibrium radionuclide angiocardiography: Its usefulness in current practice and potential future applications. World J Radiol. 2012; 4(10):421-30. PMC: 3495989. DOI: 10.4329/wjr.v4.i10.421. View

12.

Simoes M, Barthel P, Matsunari I, Nekolla S, Schomig A, Schwaiger M . Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J. 2004; 25(7):551-7. DOI: 10.1016/j.ehj.2004.02.016. View

13.

Rapezzi C, Quarta C, Guidalotti P, Pettinato C, Fanti S, Leone O . Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011; 4(6):659-70. DOI: 10.1016/j.jcmg.2011.03.016. View

14.

Tanaka M, Hongo M, Kinoshita O, Takabayashi Y, Fujii T, Yazaki Y . Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol. 1997; 29(1):168-74. DOI: 10.1016/s0735-1097(96)00438-x. View

15.

Arbab A, Koizumi K, Toyama K, Arai T, Yoshitomi T, Araki T . Scan findings of various myocardial SPECT agents in a case of amyloid polyneuropathy with suspected myocardial involvement. Ann Nucl Med. 1997; 11(2):139-41. DOI: 10.1007/BF03164822. View

16.

Falk R, Lee V, Rubinow A, Hood Jr W, Cohen A . Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol. 1983; 51(5):826-30. DOI: 10.1016/s0002-9149(83)80140-4. View

17.

Puille M, Altland K, Linke R, Kiett R, Steiner D, Bauer R . 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging. 2002; 29(3):376-9. DOI: 10.1007/s00259-001-0730-0. View

18.

Eriksson P, Backman C, Bjerle P, Eriksson A, Holm S, Olofsson B . Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. Br Heart J. 1984; 52(3):321-6. PMC: 481632. DOI: 10.1136/hrt.52.3.321. View

19.

Brambilla F, Lavatelli F, Silvestre D, Valentini V, Palladini G, Merlini G . Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. J Proteome Res. 2013; 12(12):5642-55. DOI: 10.1021/pr400583h. View

20.

Dorbala S, Vangala D, Bruyere Jr J, Quarta C, Kruger J, Padera R . Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014; 2(4):358-67. PMC: 4127145. DOI: 10.1016/j.jchf.2014.03.009. View